The White House has dropped plans for an executive order that would have given political appointees more control over National Institutes of Health grants, according to Roll Call and other outlets citing people familiar with the decision. The New York Times reported that the proposed order would have created a commission with the power to block research grants that did not align with President Trump's political agenda. The White House has not issued a public statement, so the reversal rests on sourced reporting rather than an official announcement.
For patients and researchers, the reversal removes an immediate threat to how medical research money is awarded, but not every uncertainty. A separate grant rule proposed by the White House budget office remains pending, and it is unclear whether a different version of the order could return.
NIH grants support much of the country's early work on cancer, Alzheimer's disease, rare disorders, and other conditions. Many clinical trials trace back to those awards, so changes in how they are chosen can shape which treatments reach patients years later.
A Quick Reversal After Bipartisan Pressure
The plan surfaced after a White House meeting on Friday, Sept. 18, in which Office of Management and Budget Director Russell Vought criticized NIH grantmaking, Fierce Healthcare reported, citing The Washington Post. MedicalDaily previously reported that senators from both parties pushed back on the plan before any order was issued.
Sen. Susan Collins of Maine, the Republican who chairs the Senate Appropriations Committee, sent a letter to Vought and NIH Director Jay Bhattacharya on Sept. 22 urging them not to proceed. "If the administration seeks additional reforms of NIH, I urge you to submit a legislative proposal to Congress rather than pursue an executive order," she wrote.
Sen. Patty Murray of Washington, the committee's top Democrat, welcomed the reversal but said "it shouldn't take public outcry" to protect research funding, Roll Call reported.
Administration officials had argued that NIH-funded projects were at odds with the president's priorities, according to earlier reporting. Collins' request points to where the next fight may take place: the spending bills Congress must pass to fund the government after mid-December.
The Disruptions That Did Not Go Away
The reversal does not end every change to NIH funding. A separate OMB proposal issued in May would require political appointees to review discretionary grants and expand agencies' ability to cancel awards. The stopgap funding law that runs through mid-December delays that rule, Roll Call reported, but the proposal has not been withdrawn.
Researchers also describe slower, less predictable funding. NIH has a $47.5 billion budget and sends more than 80% of it out as grants, according to NPR reporting summarized by KFF Health News. Experts told NPR that the administration has delayed funding and rerouted billions of dollars in research, disrupting researchers and patients. Administration officials say their practices further the agency's goals. Those disruptions predate the dropped order and continue regardless of it.
For households, the effect is indirect but real. Families of patients enrolled in NIH-funded trials generally do not need to take action, since the dropped order concerned how awards would be approved. Patients can ask their study team whether funding for a trial is stable and what would happen to their care if a study pauses.
Early-career scientists and university labs may feel the uncertainty most, since grant applications take months to prepare and a single delayed award can stall hiring or a study launch. Smaller research institutions with fewer backup funding sources face similar pressure, which can affect how many trial sites are available close to home for patients outside major cities.
People looking for clinical trials can search ClinicalTrials.gov and ask their specialist about options. Trial listings show the study sponsor, which can help families understand whether a study depends on federal funding. Those facing serious illness should not delay standard treatment while waiting for an experimental study.
Several questions remain open, including whether a revised order will emerge and what it would contain. The next signals will come from the White House, from appropriators writing the next spending bill before mid-December, and from any action on the OMB grant rule.
Key Questions Answered
What did the White House decide? According to news reports citing people familiar with the decision, the White House dropped a planned order that would have given political appointees more control over NIH grants.
Is this officially confirmed? No official White House announcement has been made. The reports rely on people familiar with the decision.
Could a similar order return? It is unclear. No revised order has been announced, but the administration has not publicly ruled one out.
Are other NIH funding changes still pending? Yes. An OMB rule requiring political review of discretionary grants is delayed through at least mid-December but has not been withdrawn.
Does this affect patients in clinical trials? The dropped order concerned how grants would be approved. Patients can ask their study team about a trial's funding status.
How are NIH grants chosen now? Outside scientists score applications for merit, advisory councils review them, and institute leaders make final funding decisions.
Published by Medicaldaily.com
